NKTX
Nkarta, Inc. NASDAQ Listed Jul 10, 2020$2.79
After hrs
$2.79
+0.00%
Mkt Cap $199.6M
52w Low $1.63
57.4% of range
52w High $3.65
50d MA $2.86
200d MA $2.30
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.2x
ROE
-33.3%
P/FCF
-2.4x
RSI (14)
39.70
ATR (14)
$0.22
Beta
0.67
50d MA
$2.86
200d MA
$2.30
Avg Volume
576.2K
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
6000 Shoreline Court · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | AMC | -0.39 | -0.37 | +5.1% | 3.28 | -5.2% | -6.7% | -8.2% | -6.0% | +1.5% | +0.0% | — |
| Mar 25, 2026 | AMC | -0.32 | -0.37 | -15.6% | 2.13 | +0.0% | +0.5% | -3.7% | -2.9% | +5.5% | +3.8% | — |
| Nov 10, 2025 | AMC | -0.32 | -0.29 | +9.4% | 1.96 | +0.0% | +2.6% | -2.5% | -4.1% | -0.5% | -3.2% | — |
| Aug 12, 2025 | AMC | -0.37 | -0.31 | +16.2% | 1.96 | +2.0% | +12.8% | -0.5% | +5.9% | +0.9% | -2.1% | — |
| May 14, 2025 | AMC | -0.44 | -0.43 | +2.3% | 1.87 | -4.8% | -8.0% | +1.2% | -2.3% | +5.9% | -5.6% | — |
| Mar 26, 2025 | AMC | -0.41 | -0.35 | +14.6% | 1.37 | +11.7% | +43.8% | +1.5% | -8.0% | +0.5% | +3.2% | — |
| Nov 7, 2024 | AMC | -0.37 | -0.39 | -5.4% | 3.27 | +0.6% | -2.4% | +6.3% | -10.0% | -4.6% | -7.2% | — |
| Aug 13, 2024 | AMC | -0.49 | -0.34 | +30.6% | 4.97 | +9.7% | +3.2% | -2.3% | +1.2% | +2.8% | -1.9% | — |
| May 9, 2024 | AMC | -0.56 | -0.58 | -3.6% | 6.30 | +3.2% | -0.8% | +5.3% | -0.5% | +5.0% | -0.9% | — |
| Mar 21, 2024 | AMC | -0.62 | -0.57 | +8.1% | 12.98 | -23.0% | -31.3% | +17.6% | -5.9% | +12.4% | -2.5% | — |
| Nov 9, 2023 | AMC | -0.67 | -0.52 | +22.4% | 2.05 | +6.3% | -1.0% | -5.9% | +20.4% | +7.8% | -5.0% | — |
| Aug 10, 2023 | AMC | -0.69 | -0.68 | +1.4% | 2.03 | +0.0% | -2.0% | +0.0% | -0.5% | -1.0% | -3.6% | — |
| May 11, 2023 | AMC | -0.71 | -0.63 | +11.3% | 4.47 | +7.2% | +0.4% | +3.8% | -3.6% | -0.2% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Mizuho | Maintains | Outperform → Outperform | — | $2.00 | $2.04 | +2.0% | +5.5% | +3.8% | +5.9% | +1.7% | -4.7% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $2.13 | $2.13 | +0.0% | +0.5% | -3.7% | -2.9% | +5.5% | +3.8% |
| Nov 11 | Stifel | Maintains | Buy → Buy | — | $1.96 | $1.96 | +0.0% | +2.6% | -2.5% | -4.1% | -0.5% | -3.2% |
| Aug 14 | Stifel | Maintains | Buy → Buy | — | $2.21 | $2.18 | -1.4% | -0.5% | +5.9% | +0.9% | -2.1% | -1.7% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $1.96 | $2.00 | +2.0% | +12.8% | -0.5% | +5.9% | +0.9% | -2.1% |
| Jun 10 | Mizuho | Maintains | Outperform → Outperform | — | $1.87 | $1.89 | +1.1% | +6.4% | +0.5% | -4.5% | -2.6% | +1.6% |
| May 15 | William Blair | Downgrade | Outperform → Market Perform | — | $1.87 | $1.78 | -4.8% | -8.0% | +1.2% | -2.3% | +5.9% | -5.6% |
| May 15 | Needham | Maintains | Buy → Buy | — | $1.87 | $1.78 | -4.8% | -8.0% | +1.2% | -2.3% | +5.9% | -5.6% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $1.51 | $1.46 | -3.3% | +4.0% | -2.5% | +3.3% | +7.6% | +0.6% |
| Mar 27 | Stifel | Maintains | Buy → Buy | — | $1.37 | $1.53 | +11.7% | +43.8% | +1.5% | -8.0% | +0.5% | +3.2% |
| Mar 27 | Needham | Maintains | Buy → Buy | — | $1.37 | $1.53 | +11.7% | +43.8% | +1.5% | -8.0% | +0.5% | +3.2% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.37 | $1.53 | +11.7% | +43.8% | +1.5% | -8.0% | +0.5% | +3.2% |
| Nov 21 | Mizuho | Maintains | Outperform → Outperform | — | $2.50 | $2.48 | -0.8% | -2.4% | +0.4% | +5.7% | +0.8% | +14.6% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.19 | $3.23 | +1.3% | +6.3% | -10.0% | -4.6% | -7.2% | -6.3% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $3.27 | $3.29 | +0.6% | -2.4% | +6.3% | -10.0% | -4.6% | -7.2% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.13 | $5.31 | +3.5% | -2.3% | +1.2% | +2.8% | -1.9% | +5.3% |
| Aug 14 | Needham | Maintains | Buy → Buy | — | $4.97 | $5.45 | +9.7% | +3.2% | -2.3% | +1.2% | +2.8% | -1.9% |
| Aug 14 | Raymond James | Upgrade | Outperform → Strong Buy | — | $4.97 | $5.45 | +9.7% | +3.2% | -2.3% | +1.2% | +2.8% | -1.9% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.84 | $6.73 | -1.6% | -2.9% | +4.1% | +1.9% | -5.0% | -5.1% |
| Jun 28 | Needham | Maintains | Buy → Buy | — | $5.86 | $5.91 | +0.9% | +0.9% | -1.0% | -10.1% | +1.9% | -3.4% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $5.97 | +0.0% | -1.8% | +0.9% | -1.0% | -10.1% | +1.9% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.25 | $6.30 | +0.8% | +5.3% | -0.5% | +5.0% | -0.9% | -4.3% |
| May 13 | Needham | Maintains | Buy → Buy | — | $6.25 | $6.30 | +0.8% | +5.3% | -0.5% | +5.0% | -0.9% | -4.3% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.30 | $6.50 | +3.2% | -0.8% | +5.3% | -0.5% | +5.0% | -0.9% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $8.75 | $8.49 | -3.0% | -7.9% | +9.2% | -0.7% | -0.1% | -10.8% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.49 | $10.81 | +3.1% | -5.9% | +12.4% | -2.5% | +0.1% | -8.6% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.92 | $10.47 | +17.4% | +17.6% | -5.9% | +12.4% | -2.5% | +0.1% |
| Mar 22 | Mizuho | Maintains | Buy → Buy | — | $12.98 | $10.00 | -23.0% | -31.3% | +17.6% | -5.9% | +12.4% | -2.5% |
| Mar 22 | Raymond James | Downgrade | Strong Buy → Outperform | — | $12.98 | $10.00 | -23.0% | -31.3% | +17.6% | -5.9% | +12.4% | -2.5% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.98 | $10.00 | -23.0% | -31.3% | +17.6% | -5.9% | +12.4% | -2.5% |
| Mar 22 | Needham | Maintains | Buy → Buy | — | $12.98 | $10.00 | -23.0% | -31.3% | +17.6% | -5.9% | +12.4% | -2.5% |
| Mar 5 | Mizuho | Maintains | Buy → Buy | — | $13.09 | $13.18 | +0.7% | +1.0% | +18.8% | -5.3% | -1.7% | -4.3% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.91 | $8.74 | -1.9% | -2.5% | +3.3% | -5.2% | -12.8% | +6.2% |
| Dec 12 | Needham | Maintains | Buy → Buy | — | $2.79 | $2.78 | -0.4% | -0.7% | +0.4% | +5.4% | +9.2% | -2.5% |
| Nov 16 | Mizuho | Maintains | Buy → Buy | — | $2.48 | $2.47 | -0.4% | -5.0% | +10.8% | +0.2% | -3.3% | +2.4% |
| Oct 18 | Needham | Maintains | Buy → Buy | — | $3.14 | $3.17 | +1.0% | -3.2% | -22.4% | -6.8% | -16.6% | +6.8% |
| Oct 18 | Raymond James | Upgrade | Outperform → Strong Buy | — | $3.14 | $3.17 | +1.0% | -3.2% | -22.4% | -6.8% | -16.6% | +6.8% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.14 | $3.17 | +1.0% | -3.2% | -22.4% | -6.8% | -16.6% | +6.8% |
| Oct 17 | Raymond James | Upgrade | Outperform → Strong Buy | — | $1.48 | $1.47 | -0.7% | +112.2% | -3.2% | -22.4% | -6.8% | -16.6% |
| Aug 14 | Mizuho | Maintains | Buy → Buy | — | $1.99 | $2.00 | +0.5% | +0.0% | -0.5% | -1.0% | -3.6% | -2.1% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.03 | $2.03 | +0.0% | -2.0% | +0.0% | -0.5% | -1.0% | -3.6% |
| Aug 10 | Needham | Maintains | Buy → Buy | — | $2.00 | $2.02 | +1.0% | +1.5% | -2.0% | +0.0% | -0.5% | -1.0% |
| Jun 28 | Raymond James | Maintains | Outperform → Outperform | — | $2.81 | $2.83 | +0.7% | -11.7% | -6.0% | -6.0% | -0.5% | -3.2% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.53 | $4.38 | -3.3% | -38.0% | -11.7% | -6.0% | -6.0% | -0.5% |
| Jun 27 | Needham | Maintains | Buy → Buy | — | $4.53 | $4.38 | -3.3% | -38.0% | -11.7% | -6.0% | -6.0% | -0.5% |
| May 12 | Stifel | Maintains | Buy → Buy | — | $4.47 | $4.79 | +7.2% | +0.4% | +3.8% | -3.6% | -0.2% | +0.4% |
| May 12 | Needham | Maintains | Buy → Buy | — | $4.47 | $4.79 | +7.2% | +0.4% | +3.8% | -3.6% | -0.2% | +0.4% |
| Apr 18 | Needham | Maintains | Buy → Buy | — | $4.61 | $4.65 | +0.9% | +1.1% | +3.6% | -4.1% | +3.0% | -5.9% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $3.75 | $3.70 | -1.3% | +2.4% | +1.6% | -9.7% | -4.3% | +0.0% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.70 | -1.3% | +2.4% | +1.6% | -9.7% | -4.3% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | HASTINGS PAUL J | Chief Executive Officer | Sell | 1,776 | $2.71 | $5K | 390,247 | — | — |
8-K · 2.02
!! High
Nkarta, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Nektero Therapeutics established an at-the-market offering program allowing flexible equity capital raises, potentially diluting shareholders but providing financial flexibility for development-stage biotech operations.
Mar 26
8-K
Unknown — 8-K Filing
Nkarta's workforce restructuring and clinical team expansion signal focus on autoimmune NK cell development, but cash burn concerns remain critical for investors evaluating runway to key trial milestones.
Mar 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Gsk Plc | 3,150,732 | $7M | — | Mar 2026 |
| 2 | Samsara Biocapital, Llc | 3,507,666 | $6M | Reduced | Dec 2025 |
| 3 | Monaco Asset Management Sam | 2,546,932 | $5M | Added | Dec 2025 |
| 4 | Alyeska Investment Group, L.p. | 2,084,840 | $4M | — | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 2,047,376 | $4M | Added | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 2,011,421 | $4M | New | Mar 2026 |
| 7 | Citadel Advisors Llc | 1,783,994 | $4M | Added | Mar 2026 |
| 8 | Renaissance Technologies Llc | 1,732,372 | $4M | Added | Mar 2026 |
| 9 | Wasatch Advisors Lp | 1,577,847 | $3M | — | Mar 2026 |
| 10 | Tang Capital Management Llc | 1,480,823 | $3M | Reduced | Dec 2025 |
| 11 | Acadian Asset Management Llc | 1,259,776 | $3M | Added | Mar 2026 |
| 12 | Peapod Lane Capital Llc | 676,212 | $1M | — | Mar 2026 |
| 13 | Aqr Capital Management Llc | 595,726 | $1M | Added | Mar 2026 |
| 14 | Morgan Stanley | 622,232 | $1M | Reduced | Dec 2025 |
| 15 | Jpmorgan Chase & Co | 575,001 | $1M | Reduced | Mar 2026 |
| 16 | Nuveen, Llc | 445,798 | $941K | Added | Mar 2026 |
| 17 | Northern Trust Corp | 417,172 | $880K | Added | Mar 2026 |
| 18 | D.e. Shaw & Co | 356,932 | $753K | Added | Mar 2026 |
| 19 | Panagora Asset Management Inc | 284,210 | $600K | — | Mar 2026 |
| 20 | Vanguard Portfolio Management Llc | 272,079 | $574K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$199.6M
Enterprise Value
-$64.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.11x
P/B
0.66x
P/S
—
P/FCF
-2.35x
EV/EBITDA
—
Shares Out
74.0M
Financials (TTM)
Revenue
$0
Net Income
-$99.9M
EBITDA
-$90.7M
Free Cash Flow
-$89.9M
Op Cash Flow
-$88.7M
EPS Basic
$-1.41
EPS Diluted
$-1.34
EPS Forward
$-1.45
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$404.2M
Total Liab.
$91.9M
Total Equity
$312.3M
Cash
$276.3M
LT Debt
$0
Book Value/Sh
$4.22
Debt/Equity
0.24x
Current Ratio
12.69
Quick Ratio
12.69
Returns & Growth
ROE
-33.3%
ROA
-25.8%
ROIC
-31.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+11.9%
Price Returns
2W
+15.7%
1M
+17.3%
3M
+20.4%
6M
+72.0%
12M
+86.8%
Technicals
52W High
$3.65
52W Low
$1.63
50d MA
$2.86
200d MA
$2.30
RSI (14)
39.70
ATR (14)
$0.22
Beta
0.67
Avg Volume
576K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$21.60
High
$36.00
Low
$15.00
Median
$16.00
Data updated apr 26, 2026 3:12pm
· Source: financialmodelingprep.com